Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases

Abstract Purpose   153Sm-ethylenediaminetetramethylenephosphonic acid (EDTMP; Quadramet?) is indicated for the treatment of painful bone metastases, whereas zoledronic acid (Zometa?) is indicated for the prevention of skeletal complications. Because of the different therapeutic effects, combining the treatments may be beneficial. Both, however, accumulate in areas with increased osteoblastic activity. Possible drug interactions were investigated.